We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-15.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.91B
AUM Growth
-$2.06B
Cap. Flow
+$62M
Cap. Flow %
0.63%
Top 10 Hldgs %
40.04%
Holding
153
New
17
Increased
26
Reduced
29
Closed
21

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$123M
2
WMGI
Wright Medical Group Inc
WMGI
+$120M
3
LLY icon
Eli Lilly
LLY
+$107M
4
HCA icon
HCA Healthcare
HCA
+$72.7M
5
DVAX
Dynavax Technologies
DVAX
+$70M

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$161M
2
SHPG
Shire pic
SHPG
+$153M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$120M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$119M
5
GILD icon
Gilead Sciences
GILD
+$79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Financials 0.24%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALIM
126
CALL
DELISTED
Alimera Sciences
ALIM
$442K ﹤0.01%
+13,333
New +$751K
ABBV icon
127
CALL
AbbVie
ABBV
$465B
– –
-300,000
Closed -$20.2M
ADVM
128
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-25,000
Closed -$4.06M
BMY icon
129
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-500,000
Closed -$33.3M
CARM
130
DELISTED
Carisma Therapeutics
CARM
– –
-36,580
Closed -$2.06M
IMUX icon
131
PUT
Immunic
IMUX
$182M
– –
-188
Closed -$1.58M
OSUR icon
132
OraSure Technologies
OSUR
$277M
– –
-1,550,300
Closed -$8.36M
PODD icon
133
Insulet
PODD
$11.6B
– –
-453,000
Closed -$14M
PTCT icon
134
PUT
PTC Therapeutics
PTCT
$6.25B
– –
-50,000
Closed -$2.41M
SPY icon
135
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
– –
-200,000
Closed -$41.2M
DRNA
136
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-141,900
Closed -$1.98M
AGN
137
CALL
DELISTED
Allergan plc
AGN
– –
-25,000
Closed -$7.59M
ONCE
138
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-166,500
Closed -$10M
ARRY
139
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-500,000
Closed -$3.6M
SGYP
140
CALL
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-250,000
Closed -$2.08M
IPXL
141
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-150,000
Closed -$6.89M
CEMP
142
DELISTED
Cempra, Inc.
CEMP
– –
-50,000
Closed -$1.72M
TRNX
143
DELISTED
TORNIER N V SHARES (NLD)
TRNX
– –
-4,805,000
Closed -$120M
RCPT
144
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-628,100
Closed -$119M
MRGE
145
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
– –
-3,308,400
Closed -$15.9M
PDLI
146
CALL
DELISTED
PDL BioPharma, Inc.
PDLI
– –
-380,000
Closed -$2.44M
MDVN
147
DELISTED
MEDIVATION, INC.
MDVN
– –
-2,826,800
Closed -$161M
2 3 4 5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2015 Portfolio in Review

As of Q3 2015, OrbiMed held 153 positions worth $9.91B, down 17% from $12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2015 filing shows 17 new, 26 increased, 29 reduced and 21 closed positions. Its largest new stake was Eli Lilly: 1,272,000 shares worth $106M. The largest sale was MEDIVATION, INC., an estimated $161M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2015 buy was Eli Lilly: 1,272,000 shares worth $106M.
  • OrbiMed added most to Teva Pharmaceuticals in Q3 2015, an estimated $123M increase.
  • OrbiMed's biggest Q3 2015 reduction was Shire pic, cutting an estimated $153M.
  • OrbiMed fully exited MEDIVATION, INC. in Q3 2015, selling an estimated $161M.
  • OrbiMed's ten largest holdings make up 40% of its $9.91B portfolio in Q3 2015.
  • OrbiMed opened 17 new positions and closed 21 in Q3 2015.
  • OrbiMed's portfolio value fell 17% quarter-over-quarter to $9.91B.

Based on OrbiMed's 13F filing for Q3 2015, filed 13 Nov 2015.